HC Wainwright & Co. Maintains Buy on Insmed, Raises Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein maintains a Buy rating on Insmed (NASDAQ:INSM) and raises the price target from $52 to $70.
May 29, 2024 | 10:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein maintains a Buy rating on Insmed and raises the price target from $52 to $70.
The raised price target from $52 to $70 by a reputable analyst suggests strong confidence in Insmed's future performance, likely leading to positive investor sentiment and a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100